IGF1R and neoplasm: Combining an anti-IGF1R antibody with MEDI-573 offers a better antitumor effect because of greater inhibition of IGF1 and IGF2 signaling in cancer cells and tumor angiogenesis is inhibited (45) (Figure 2).